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ABSTRACT
Background: A case in which a 45-year-old female
patient with peritonitis experienced immediate-type
hypersensitivity on two occasions after administration
of preparations containing six different medications
was referred to us for closer inspection.
Methods/Results: Skin tests performed on the six
medications revealed a positive reaction to the vitamin
B6 preparation Biosechs (Wakamoto Pharmaceutical,
Tokyo, Japan). Further investigation showed that the
principal ingredient, pyridoxal 5′-phosphate (PLP),
produced a positive reaction, whereas the injection
solvent with the principal ingredient removed pro-
duced a negative reaction. When compounds similar
to PLP were tested, pyridoxine (PN), pyridoxamine and
pyridoxal produced a negative reaction, whereas pyri-
doxine 5′-phosphate and pyridoxamine 5′-phosphate
(PMP) produced a positive reaction. Adenosine 2′-
phosphate and adenosine 5′-diphosphate were also
tested and these produced a negative reaction. When
a histamine-release test was performed, PLP and PMP
produced a positive reaction, whereas PN produced a
negative reaction. When all tests were performed on
three control subjects, the results were all negative.
Conclusions: In this very rare case, phosphate
radical conjugates with a pyridine nucleus became
haptenic-epitope and an immediate-type reaction
occurred. In past cases involving hypersensitivity to
vitamin B6, two cases involved a photoallergic reaction
caused by PN and one case involved an immediate-
type hypersensitivity caused by PLP. In the past cases,
closely related substances had not been tested and an
epitope was not identified.
Key words: cross-reactivity, haptenic epitope, histamine-
release test, immediate-type hypersensitivity, skin test,
vitamin B6.
INTRODUCTION
Vitamin B6 is a soluble vitamin that was discovered in
1934 by Gyõrgy1 while investigating factors preventing
dermatitis in rats. Vitamin B6 has three forms: pyridoxine
(PN), pyridoxal (PL) and pyridoxamine (PM). In the living
body, vitamin B6 is readily taken up by cells and phospho-
rylation occurs under Mg and Zn by action of pyri-
doxal kinase, producing pyridoxine 5′-phosphate (PNP),
pyridoxal 5′-phosphate (PLP) and pyridoxamine 5′-
phosphate (PMP). Pyridoxine 5′-phosphate oxidase
causes PNP and PMP to further transform into PLP. Inside
cells, the content of the phosphorylated form, predomi-
nantly PLP and PMP, far outweighs the free-form of
vitamin B6.2 Pyridoxal 5′-phosphate and PMP work as
coenzymes for amino acids and carbohydrate metabo-
lism and play an important role in the propagation and
differentiation of cells.3 Although it is difficult to imagine
how the physiologically working vitamin B6 can become
an allergen, on rare occasions there are reports of hyper-
sensitivity occuring when vitamin B6 was administered in a
medication. In the present study, we examined a case
where an immediate-type hypersensitivity occurred after
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the PLP-based Biosechs (Wakamoto Pharmaceutical,
Tokyo, Japan) was administered. We also investigated
cross-reactivity and possible antigenic determinants by
testing PLP and similar substances in vivo and in vitro.
Case report
The patient was a 45-year-old female with no family
history of atopy. In April 1993, the patient underwent
surgery to remove the right ovary due to an ovarian 
cyst. In April 1995, the patient sought treatment at a local
hospital for sudden abdominal pain. The patient was
diagnosed with postoperative adhesive ileus and peri-
tonitis. Upon admission, the patient received a saline
transfusion containing Buscopan (Tanabe Pharma-
ceutical, Osaka, Japan) and a vitamin preparation.
Directly following this, the patient experienced wide-
spread pruritus. The transfusion was stopped and the
patient’s condition improved with rest and she was sub-
sequently discharged. On 12 November 1997, the
patient again sought treatment at the local hospital for
abdominal pain. The patient was diagnosed with recur-
rent postoperative adhesive ileus and peritonitis. Upon
admission, the patient received the same transfusion as
on the previous occasion. Approximately 10 min into the
transfusion, the patient was observed to have full body
flushing, low blood pressure and blurred conscious-
ness. The transfusion was stopped and, after a steroid
was administered systemically, the patient’s condition
improved and she was discharged. The case was then
referred to us for closer inspection.
Physical examination of the patient revealed a middle-
aged woman of medium height and medium build in
good nutritional condition. No organ abnormalities in the
region of the thorax and abdomen were noted. No signs
of erythema, wheal or edema on the skin were present.
Laboratory investigations revealed leukocytes of 
8500/mm3 (neutrophils 60.7%, eosinophils 1.2%,
basophils 6.4%, lymphocytes 33.8%, monocytes 3.9%).
No abnormal hepatic function was found. The serum IgE
level was 161.0 IU/mL.
METHODS
Skin tests
Skin test of the administered medication
To determine which medication was the cause of the
patient’s reaction, a prick test (Table 1) was performed on
the patient using various concentrations of each of the 
six medications administered during the transfusion. For
medications that produced a negative reaction in the
Table 1 Reagents and results of skin testing using prescribed drugs
Reagents Concentration Prick Scratch Intradermal
test test test
Buscopan (scopolamine butylbromide 20 mg/mL; 
Tanabe Pharmaceutical, Osaka, Japan) As is – – –
Metabolin (thiamine 50 mg/mL; 
Takeda Pharmaceutical, Osaka, Japan) As is – – –
Fravitan (FAD 10 mg/mL;
Toa-eiyo Pharmaceutical, Tokyo, Japan) As is – – –
Biosechs (pyridoxal phospate 10 mg/mL; 
Wakamoto Pharmaceutical, Tokyo, Japan) As is + ND ND
1.0 mg/mL + ND ND
0.1 mg/mL + ND ND
0.01 mg/mL – ND ND
Ascoltin (ascorbic acid 100 mg/mL; 
Tokyo Tanabe Pharmaceutical, Tokyo, Japan) As is – – –
Keywan (phytonadione 10 mg/mL; 
Eizai Pharmaceutical, Tokyo, Japan) As is – – –
Normal saline As is – – –
Prick test15 reactions were read at 15 min and a wheal larger than 5 mm mean diameter or erythema larger than 15 mm mean diameter was
recorded as positive; scratch test reactions were read at 15 min and a wheal wider than 5 mm transverse diameter or erythema wider than 15 mm
transverse diameter was recorded as positive; intradermal test15 reactions were read at 15 min and a wheal larger than 9 mm mean diameter or
erythema larger than 21 mm mean diameter was recorded as positive (+).
FAD, flavin adenine dinucleotide; ND, not done.
prick test, scratch and intradermal tests were performed
in that order. For control purposes, three age-matched
women of normal health were administered the same
tests as the patient. All tests were performed after fully
informed consent had been obtained.
Skin test of Biosechs
From the above tests, the medication that caused the
reaction in the patient was found to be Biosechs, the
principal component of which is PLP. A skin test (Table 2)
was performed using a dilution series prepared from 
a physiological saline solution of this PLP (Chugai
Pharmaceutical, Tokyo, Japan). A skin test was also
performed using the injection solvent with the PLP
removed (consisting of sodium bisulfate, benzyl alcohol,
hydrochloric acid and sodium hydroxide). For control
purposes, three women of normal health were adminis-
tered the same tests as the patient.
Skin test of compounds chemically related to PLP
Other than PLP, skin tests (Table 3; Fig. 1) were performed
in the following order using PMP (Sigma Chemical Co.,
St Louis, MO, USA), PNP and PL-HCl (Takeda Chemical
Industries, Tokyo, Japan), PN-HCl (Sigma Chemical Co.),
adenosine 5′-diphosphate (Sigma Chemical Co.) and
adenosine 2′-phosphate (Sigma Chemical Co.). The PNP
was synthesized and supplied by Taiho Pharmaceutical
(Tokyo, Japan).
Histamine-release test
After considering the results of the skin tests, three prepa-
rations (PLP, PMP and PN-HCl) were used as allergens 
in a histamine-release test (HRT) of the peripheral 
blood of the patient and the three control subjects. An
Immunotech histamine enzyme-linked immunosorbent
assay kit (Immunotech A; Beckman Coulter Company,
Marseille, France) was used for this test. The test proce-
dure followed the directions supplied with the kit. Briefly,
heparinized venous blood was diluted and the allergen
was added to the blood. After incubating for 30 min at
37°C, the sample was centrifuged and the supernatant
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Table 2 Reagents and results of skin testing using Biosechs (Wakamoto Pharmaceutical, Tokyo, Japan) ingredient and solvent
Reagents Concentration Prick Scratch Intradermal
(mg/mL) test test test
Pyridoxal 5′-phosphate 10 + ND ND
1 + ND ND
0.1 – – –
0.01 – – –
Solvent* – – –
Normal Saline – – –
*The solvent for Biosechs excluded pyridoxal 5′-phosphate and was composed of sodium bisulfate, benzyl alcohol, hydrochloric acid and sodium
hydroxide.
ND, not done.
Table 3 Skin testing using vitamin B6 derivatives and related
compounds
Reagents Concentration Prick Scratch Intradermal
(mg/mL) test test test
PMP 1 + ND ND
0.1 + ND ND
0.01 – ND ND
PNP 1 – – +
0.1 – – +
0.01 – – +
0.001 ND ND +
0.0001 ND ND –
PN-HCl 1 – – –
0.1 – – –
0.01 – – –
PL-HCl 1 – – –
0.1 – – –
0.01 – – –
ADP 1 – – –
0.1 – – –
0.01 – – –
AMP 1 – – –
0.1 – – –
0.01 – – –
PMP, pyridoxamine 5′-phosphate; PNP, pyridoxine 5′-phosphate;
PN-HCl, pyridoxine hydrochloride; PL-HCl, pyridoxal hydrochloride;
ADP, adenosine 2′-diphosphate; AMP, adenosine 5′-phosphate.
was taken as the specimen. An acylation solution was
added to the specimen as well as to a series of histamine
standard solutions. After agitation, this solution and
enzyme-labeled acylated histamine was added to a
microcup coated with anti-acylated histamine mono-
clonal antibody and left at 4°C for 18 h for a competitive
reaction to take place. After the microcup was washed, a
substrate solution (P-nitrophenyl phosphate) was added
and the mixture was left at 23°C for 30 min. After a stop
solution was added to the mixture, absorbance was
measured at 410 nm and the histamine concentration
was calculated. All measurements were performed in
duplicate and reoccurence was confirmed on three inde-
pendent experiments.
To assess total histamine, 950 µL distilled water was
added to 50 µL venous blood. This solution was frozen
and thawed twice and the supernatant of the lyzed cell
suspension was acylated as described above. To assess
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Fig. 1 Molecular structures of
the chemical reagents used in
the present study.
spontaneous histamine release, histamine release 
buffer was added instead of allergen solution and was
processed in the same manner as other tubes.
Released histamine was express as a percentage and
calculated as follows:
% Histamine release = (Histamine in allergen
stimulation – Histamine in spontaneous release)/(Total
histamine – Histamine in spontaneous release) × 100
Lymphocyte stimulation tests
Lymphocyte stimulation tests (LST) were performed using
standard methods in order to further investigate the case
in vitro. For use as antigens, three dilutions of two prepa-
rations, namely PLP and PN, were prepared for testing
and mononuclear leukocytes were separated from the
heparinized venous blood of the patient and three
healthy subjects. The antigen solution was then added to
the mononuclear leukocytes. After being left to incubate
at 37°C for 70 h, [3H]-thymidine (18.5 MBq) was added
to the mixture and it was left for an additional 2 h. A scin-
tillation counter was used to measure the radioactivity of
the [3H]. A stimulation index was calculated using the
following equation:
Stimulation index (%) = (([3H] in the group with
medication)/([3H] in the group without medication)) × 100
The same test was administered to three healthy subjects
who functioned as a control group.
Statistical analysis
The non-parametric Mann–Whitney U-test was used for
the statistical analysis or results from the HRT and LST and
P < 0.05 was taken as the level of significance.
RESULTS
Skin test
Skin test of administered medication
Of the six administered medications, only the vitamin B6
preparation Biosechs produced a positive reaction during
the prick tests (Fig. 2). The other medications produced 
a negative reaction to the prick, scratch and intradermal
tests. When four dilutions of Biosechs were tested, a
positive reaction to the test solution was produced in the
patient by prick test until a concentration of 0.1 mg/mL
solution. The three normal control participants produced
negative reactions to all six medications (Table 1).
Skin test of Biosechs
In prick tests that were performed using a dilution series
prepared from physiological saline and PLP (the principal
component of Biosechs), a positive reaction was exhib-
ited by the patient until a concentration of 1 mg/mL 
was used (Table 2). The reason for the different positive
threshold compared with the results for diluted Biosechs
in Table 1 is thought to be because of the dissolution of
PLP in physiological saline before use resulting in a dif-
ferent pH of the solution and a reduced activity. The
Biosechs solvent alone, with the PLP removed, produced
negative reactions in the patient, even following intrader-
mal tests. All three healthy control subjects had negative
reactions to the prick, scratch and intradermal tests at a
dilution of 10 mg/mL PLP.
Skin test of compounds chemically related to PLP
In tests that investigated the effects of PLP and PMP, 
the prick test produced positive reactions in the patient up
until a dilution of 0.1 mg/mL and when a 0.01 mg/mL
solution was tested, this solution produced a negative
reaction. In tests that used PNP, both the prick and scratch
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Fig. 2 Positive prick test for Biosechs (Wakamoto Pharma-
ceutical, Tokyo, Japan). After 1 drop of solution was applied to
the forearm skin, a 27 G syringe was used to prick the skin
through the solution. After 15 min, the Biosechs test had devel-
oped a wheal measuring 2 × 3 mm and erythema measuring
15 × 18 mm, whereas the physiological saline test had devel-
oped a wheal measuring 1 × 1 mm and erythema measuring 
4 × 4 mm. For the three control subjects, the wheal developed
to both Biosechs and physiological saline was < 2 mm in mean
diameter and the erythema was < 8 mm in mean diameter.
NS, normal saline.
tests produced negative reactions for all concentrations
investigated. However, in the intradermal test, a positive
reaction was produced in the patient with solutions up 
to 0.001 mg/mL (Table 3). All tests in the three control
subjects produced negative reactions. The pyridine com-
pounds without phosphate radicals (PN-HCl and PL-HCl)
produced negative reactions in all tests (prick, scratch
and intradermal tests) in both the patient and healthy
controls. Similar negative results were observed for
adenosine 5′-diphosphate and adenosine 2′-phosphate,
both of which have a preserved phosphate radical but
have had the pyridine nucleus replaced with another
structure (Table 3).
Histamine-release test
On the basis of results of the skin tests, PLP, PMP and 
PN-HCl, used as antigens in the HRT, were diluted into
100, 10, 1.0 and 0.1 ng/mL solutions (Fig. 3).
When PLP was used in the HRT, the mean (±SD) %
histamine release from the patient’s blood with a 
100 ng/mL solution was 3.93 ± 0.68, whereas the
mean % histamine release for the three control partici-
pants was 0.33 ± 0.14, 1.37 ± 0.79 and 0.50 ± 0.13,
indicating a significant increase in % histamine release in
the patient’s blood (P < 0.02).
When PMP was used to stimulate the blood at a
concentration of 100 ng/mL, the % histamine release of
the patient’s blood was 3.08 ± 1.10, whereas the % his-
tamine release of the three control participants was 0.11
± 0.09, 1.17 ± 0.09 and 0.30 ± 0.00. The increase in
histamine release from the patient’s blood was highly sig-
nificant (P < 0.02). However, when PN-HCl (which does
not have phosphate radicals) was used at a concentra-
tion of 100 ng/mL, the histamine release from the
patient’s blood was similar to the histamine release of the
three control subjects and no evidence of increased hist-
amine release from the patient’s blood was seen. The
results were similar in the intradermal test. The mean
spontaneous histamine release of the patient’s blood in
these experiments was 8.76 ± 2.44 mmol/L and the
mean total histamine release was 516.93 ± 5.96
mmol/L.
Lymphocyte stimulation tests
No increase in the stimulation index was observed in the
patient’s blood following stimulation with any concentra-
tion of PLP and PN-HCl. These results were similar to
those obtained for the three control subjects (data not
shown) and support the idea that LST is predominantly a
reflection of cellular immune activity.
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Fig. 3 Histamine release test. A significant increase 
(*P < 0.02) in histamine was observed when using (a) pyri-
doxal 5′-phosphate and (b) pyridoxamine 5′-phosphate. (c) No
significant release of histamine was observed when using
pyridoxine hydrochloride. (), patient; (), control subject 1;
(), control subject 2; (), control subject 3.
DISCUSSION
Vitamin B6 is a physiological substance that plays an
important role in the metabolism of amino acids and
carbohydrates inside living bodies. Pyridoxal 5′-phos-
phate is the active form of vitamin B6 that occurs inside
cells and it is hard to imagine of PLP itself functioning as
an allergen inside a living body. Nevertheless, when
administered as a medical preparation, an allergic reac-
tion to PLP can, on rare occasions, occur and, in the past,
there have been three reported cases of such an allergy
occurring.4–6 Two of these cases involved a photoallergic
drug eruption caused by PN-HCl6 or pyritinol,5 which is a
compound consisting of two PN molecules bonded by a
disulfide linkage. The other case4 was the same as the
case presented herein, in which an immediate-type aller-
gic reaction was caused by PLP and a positive reaction
was acquired following a scratch test and the skin window
technique using a 1% PLP solution. However, the reac-
tions with PMP, PNP, PL and PN, and other agents, were
not studied and, with regard to speculation on the mech-
anism of hypersensitivity, the authors of this case report
pointed out the possibility of an allergic reaction caused
by impurities contained in the preparation or the possibil-
ity of patient’s mast cells becoming hypersensitive to PLP
in a-non-allergic way.4
Contrary to the findings of the previous case, we have
shown, by performing skin reaction tests and HRT, that
our patient has hypersensitivity and that there was a reac-
tion to the principal agent of the injection administered to
the patient, but not a reaction to the solvent. There was a
reaction to PLP, PMP and PNP, but no reaction to PL and
PN. Furthermore, there was no reaction to adenosine 
5′-diphosphate and adenosine 2′-phosphate, similar
compounds that contain phosphate side chains. From
this, we speculate that it could be an allergic reaction that
is only valid with PLP, PMP and PNP, which have a pyridine
nucleus and also phosphate radicals attached. This raises
the question of how these compounds, which are
metabolites of vitamin B6 inside the cells,2 have acquired
antigenic properties.
The molecular basis of antigen presentation in drug
allergy has not been fully elucidated. In general, imma-
ture dendritic cells in the peripheral tissue take up
exogenous antigens as antigen-presenting cells (APC)
through phagocytosis and macropinocytosis. The inter-
nalized antigen gets broken down into peptide fragments
in acidic organelles, such as endosomes and lysosomes,
by protease and is combined with major histocompatibil-
ity complex (MHC) class II molecules that can then be
observed on the cell surface. However, recently class I
molecules have also been observed to be capable of pre-
senting foreign antigens.8,9 Moreover, CD1 molecules
have also been found to be capable of being antigen-
presenting elements.10 Following antigen presentation, 
T cell receptor (TCR) signaling is the next decisive 
factor in the initiation of a specific immune reaction. The
T cell response, which includes Th1/Th2 polarization, is
affected by various types of antigens, doses, costimula-
tory factors and cytokine signals that are accessible to
antigen-specific T cells.
Allergy to medication is analogous to other chemical
haptens in that the ability of any drug to induce an
immune reaction depends on its reactivity with proteins.
The molecular targets of such a haptenation process may
be soluble or cell-bound proteins, including MHC mole-
cules and associated peptides.
The nature of the hapten determinant has only recently
started to be investigated. In the case of penicillin
allergy,11 the antigenic determinant contacted by the spe-
cific TCR is formed by the contribution of both the side
chain and backbone structures of the penicillin molecule.
The penicillin-specific T cell response is MHC restricted,
with a strong predominance of human leukocyte antigen-
DR restriction for CD4+ T cell clones.12 Penicillin can
also be presented to specific T cells by glutaraldehyde-
fixed autologous B cells, implying the covalent formation
of antigenic epitopes without the requirement of intra-
cellar processing.13 Concerning metal allergy,14 metals,
via their chemically reactive groups, could attach them-
selves to peptides bound to MHC molecules and induce 
MHC-restricted responses to the conjugates. The metals
themselves may not necessarily have been internalized by
APC.
When we consider vitamin B6, it is hard to imagine 
that the APC is including it as a foreign substance, even
when PL and PLP, which are intrinsic physiological sub-
stances, are administered as medication in large doses.
However, just like penicillin allergy and metal allergy, 
we cannot rule out the possibility of vitamin B6 com-
bining with peptides residing in either the MHC grooves
of APC or B cells or with CD1 molecules and being
recognized by TCR and turning on signals. Vitamin B6
found in the diet exists in minute quantites (0.01 mg/g
in chicken) and vitamin B6 levels in plasma are 20–
30 mmol/L (0.0053–0.0079 mg/mL), which are far
below the threshold of the hypersensitivity reaction.
Pyridoxal 5′-phosphate, PMP and PNP, which occurs in
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comparatively larger quantities, are inside cells. Because
of this, they have no opportunity to come into contact with
MHC. Therefore, even after sensitization has been estab-
lished, an immune reaction does not occur. From this,
one can understand why hypersensitivity to vitamin B6
occurs only rarely and a reaction only occurs when
vitamin B6 is administered as a medication, even with an
established sensitization.
Physiological substances such as vitamins are often
treated as substances that are safe to be administered as
medications. However, when large dosages are adminis-
tered intravenously all at once, the patient should be
monitored for the occurence of hypersensitivity.
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